telomere.digital

At the terminus of every linear chromosome lies a region of repetitive non-coding DNA — TTAGGG, repeated several thousand times — bound into a closed loop by a six-protein scaffold called shelterin. These are the telomeres, the molecular caps that prevent the cell's hereditary archive from unspooling into chaos.

Each cellular division costs the cell a fraction of these caps. Fifty to two hundred base pairs vanish per round, an erosion measured in nucleotides and decades. When the loops grow too short to remain closed, the chromosome ends are read by repair machinery as broken DNA. The cell, rather than risk the misread, withdraws into senescence — or, more rarely, abandons restraint entirely and becomes cancerous.

In 1984, in a laboratory in Berkeley, Carol Greider and Elizabeth Blackburn isolated a ribonucleoprotein that — against all expectation — added telomeric repeats back to chromosome ends. They called it telomerase. It carries its own RNA template; it writes DNA against time.

Most adult somatic cells silence the enzyme; germ cells, stem cells, and most cancers do not. Three decades of research have asked the obvious dangerous question: can we reactivate telomerase in tissues without inviting tumor formation? Gene therapy trials in mice — AAV vectors carrying TERT — extend healthy lifespan by roughly 24%. Human trials remain at the doorway.